Chapter 15 Nociceptive Behavior Induced by the Endogenous Opioid Peptides Dynorphins in Uninjured Mice. Evidence with Intrathecal N-Ethylmaleimide Inhibiting Dynorphin Degradation

International Review of Neurobiology

Volumn 85, Issue , 2009, Pages 191-205

  Tan No, Koichi ^a   Takahashi, Hiroaki ^a   Nakagawasai, Osamu ^a   Niijima, Fukie ^a   Sakurada, Shinobu ^a   Bakalkin, Georgy ^b   Terenius, Lars ^c   Tadano, Takeshi ^a  

^a TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^b UPPSALA UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 7 CHLOROKYNURENIC ACID; CYSTEINE PROTEINASE; DIZOCILPINE; DYNORPHIN; DYNORPHIN A; DYNORPHIN B; IFENPRODIL; KAPPA OPIATE RECEPTOR; MORPHINE; N ETHYLMALEIMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ A [4-10][5 TYROSINE 6,8,9 DEXTRO TRYPTOPHAN 10 LYSINE]; ION CHANNEL;

ALLODYNIA; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HYPERALGESIA; MORPHINE TOLERANCE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; SPINAL CORD; SYNAPTIC TRANSMISSION; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG POTENTIATION; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; MOUSE; PAIN; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CYSTEINE ENDOPEPTIDASES; DYNORPHINS; ETHYLMALEIMIDE; INJECTIONS, SPINAL; ION CHANNELS; MICE; MODELS, BIOLOGICAL; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 67650046032     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(09)85015-0     Document Type: Review

References (72)

1. Arcaya J.L., Cano G., Gomez G., Maixner W., and Suarez-Roca H. Dynorphin A increases substance P release from trigeminal primary afferent C-fibers. Eur. J. Pharmacol. 366 (1999) 27-34
2. Bakshi R., and Faden A.I. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res. 507 (1990) 1-5
3. Caudle R.M., and Dubner R. Ifenprodil blocks the excitatory effects of the opioid peptide dynorphin 1-17 on NMDA receptor-mediated currents in the CA3 region of the guinea pig hippocampus. Neuropeptides 32 (1998) 87-95
4. Caudle R.M., and Mannes A.J. Dynorphin: Friend or foe?. Pain 87 (2000) 235-239
5. Caudle R.M., Chavkin C., and Dubner R. κ2 Opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells. J. Neurosci. 14 (1994) 5580-5589
6. Chizh B.A., Headley P.M., and Tzschentke T.M. NMDA receptor antagonists as analgesics: Focus on the NR2B subtype. Trends Pharmacol. Sci. 22 (2001) 636-642
7. Chizh B.A., Reiβmuller E., Schlutz H., Scheede M., Haase G., and Englberger W. Supraspinal vs spinal sites of the antinociceptive action of the subtype-selective NMDA antagonist ifenprodil. Neuropharmacology 40 (2001) 212-220
8. Costigan M., and Woolf C.J. No DREAM, no pain. Closing the spinal gate. Cell 108 (2002) 297-300
9. Day R., and Akil H. The posttranslational processing of prodynorphin in the rat anterior pituitary. Endocrinology 124 (1989) 2392-2405
10. Dickenson A.H., Chapman V., and Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen. Pharmacol. 28 (1997) 633-638
11. Dores R.M., and Akil H. Steady state levels of pro-dynorphin-related end products in the striatum and substantia nigra of the adult rhesus monkey. Peptides 6 Suppl. 2 (1985) 143-148
12. Dores R.M., and Akil H. Species-specific processing of prodynorphin in the posterior pituitary of mammals. Endocrinology 120 (1987) 230-238
13. Draisci G., Kajander K.C., Dubner R., Bennett G.J., and Iadarola M.J. Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res. 560 (1991) 186-192
14. Dubner R., and Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 15 (1992) 96-103
15. Fischli W., Goldstein A., Hunkapiller M.W., and Hood L.E. Isolation and amino acid sequence analysis of a 4,000-dalton dynorphin from porcine pituitary. Proc. Natl. Acad. Sci. USA 79 (1982) 5435-5437
16. 3H] ifenprodil binding in rat brain. Eur. J. Pharmacol. 266 (1994) 67-77
17. Hauser K.F., Foldes J.K., and Turbek C.S. Dynorphin A (1-13) neurotoxicity in vitro: Opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp. Neurol. 160 (1999) 361-375
18. Hooke L.P., He L., and Lee N.M. Dynorphin A modulates acute and chronic opioid effects. J. Pharmacol. Exp. Ther. 273 (1995) 292-297
19. Iadarola M.J., Brady L.S., Draisci G., and Dubner R. Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: Stimulus specificity, behavioral parameters and opioid receptor binding. Pain 35 (1988) 313-326
20. Kajander K.C., Sahara Y., Iadarola M.J., and Bennett G.J. Dynorphin increases in the dorsal spinal cord in rats with a painful peripheral neuropathy. Peptides 11 (1990) 719-728
21. Kangawa K., Minamino N., Chino N., Sakakibara S., and Matsuo H. The complete amino acid sequence of α-neo-endorphin. Biochem. Biophys. Res. Commun. 99 (1981) 871-878
22. Kuzmin A., Madjid N., Terenius L., Ogren S.O., and Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 31 (2006) 1928-1937
23. Laughlin T.M., Vanderah T.W., Lashbrook J., Nichols M.L., Ossipov M., Porreca F., and Wilcox G.L. Spinally administered dynorphin A produces long-lasting allodynia: Involvement of NMDA but not opioid receptors. Pain 72 (1997) 253-260
24. Laughlin T.M., Larson A.A., and Wilcox G.L. Mechanisms of induction of persistent nociception by dynorphin. J. Pharmacol. Exp. Ther. 299 (2001) 6-11
25. Long J.B., Rigamonti D.D., Oleshansky M.A., Wingfield C.P., and Martinez-Arizala A. Dynorphin A-induced rat spinal cord injury: Evidence for excitatory amino acid involvement in a pharmacological model of ischemic spinal cord injury. J. Pharmacol. Exp. Ther. 269 (1994) 358-366
26. Malan T.P., Ossipov M.H., Gardell L.R., Ibrahim M., Bian D., Lai J., and Porreca F. Extraterritorial neuropathic pain correlates with multisegmental elevation of spinal dynorphin in nerve-injured rats. Pain 86 (2000) 185-194
27. Marinova Z., Yakovleva T., Meltzig M., Hallberg M., Nylander I., Ray K., Rodgers D.W., Hauser K.F., Ekström T.J., and Bakalkin G. A novel soluble protein factor with non-opioid dynorphin A-binding activity. Biochem. Biophys. Res. Commun. 321 (2004) 202-209
28. Merg F., Filliol D., Usynin I., Bazov I., Bark N., Hurd Y.L., Yakovleva T., Kieffer B.L., and Bakalkin G. Big dynorphin as a putative endogenous ligand for the κ-opioid receptor. J. Neurochem. 97 (2006) 292-301
29. Obara I., Mika J., Schafer M.K., and Przewlocka B. Antagonists of the kappa-opioid receptor enhance allodynia in rats and mice after sciatic nerve ligation. Br. J. Pharmacol. 140 (2003) 538-546
30. Ogura M., and Kita H. Dynorphin exerts both postsynaptic and presynaptic effects in the globus pallidus of the rat. J. Neurophysiol. 83 (2000) 3366-3376
31. Persson S., Post C., Alari L., Nyberg F., and Terenius L. Increased neuropeptide-converting enzyme activities in cerebrospinal fluid of opiate-tolerant rats. Neurosci. Lett. 107 (1989) 318-322
32. Pohl M., Ballet S., Collin E., Mauborgne A., Bourgoin S., Benoliel J.J., Hamon M., and Cesselin F. Enkephalinergic and dynorphinergic neurons in the spinal cord and dorsal root ganglia of the polyarthritic rat-in vivo release and cDNA hybridization studies. Brain Res. 749 (1997) 18-28
33. Randic M., Cheng G., and Kojic L. Kappa-opioid receptor agonists modulate excitatory transmission in substantia gelatinosa neurons of the rat spinal cord. J. Neurosci. 15 (1995) 6809-6826
34. 3H] MK-801 binding to the N-methyl-d-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines. J. Neurochem. 51 (1988) 830-836
35. Riley R.C., Zhao Z.Q., and Duggan A.W. Spinal release of immunoreactive dynorphin A (1-8) with the development of peripheral inflammation in the rat. Brain Res. 710 (1996) 131-142
36. Rock D.M., and Macdonald R.L. The polyamine spermine has multiple actions on N-methyl-d-aspartate receptor single-channel currents in cultured cortical neurons. Mol. Pharmacol. 41 (1992) 83-88
37. Ruda M.A., Iadarola M.J., Cohen L.V., and Young III W.S. In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. Proc. Natl. Acad. Sci. USA 85 (1988) 622-626
38. 2+ currents and secretion in isolated neuroendocrine nerve terminals. J. Neurosci. 17 (1997) 6565-6574
39. 3H] N-(1-[thienyl] cyclohexyl) piperidine binding to the N-methyl-d-aspartate receptor ionophore complex. Mol. Pharmacol. 37 (1990) 572-577
40. Schmauss C., and Herz A. Intrathecally administered dynorphin-(1-17) modulates morphine-induced antinociception differently in morphine-naïve and morphine-tolerant rats. Eur. J. Pharmacol. 135 (1987) 429-431
41. Seizinger B.R., Grimm C., Hollt V., and Herz A. Evidence for a selective processing of pro-enkephalin B into different opioid peptide forms in particular regions of rat brain and pituitary. J. Neurochem. 42 (1984) 447-457
42. Shukla V.K., and Lemaire S. Nonopioid effects of dynorphins: Possible role of the NMDA receptor. Trends Pharmacol. Sci. 15 (1994) 420-424
43. Skilling S.R., Sun X., Kurtz H.J., and Larson A.A. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: Possible roles in paralysis and neurotoxicity. Brain Res. 575 (1992) 272-278
44. Silberring J., and Nyberg F. A novel bovine spinal cord endoprotease with high specificity for dynorphin B. J. Biol. Chem. 264 (1989) 11082-11086
45. Silberring J., Castello M.E., and Nyberg F. Characterization of dynorphin A-converting enzyme in human spinal cord. An endoprotease related to a distinct conversion pathway for the opioid heptadecapeptide?. J. Biol. Chem. 267 (1992) 21324-21328
46. Silberring J., Demuth H.U., Brostedt P., and Nyberg F. Inhibition of dynorphin converting enzymes from human spinal cord by N-peptidyl-O-acyl hydroxylamines. J. Biochem. 114 (1993) 648-651
47. Tan-No K., Taira A., Sakurada T., Inoue M., Sakurada S., Tadano T., Sato T., Sakurada C., Nylander I., Silberring J., Terenius L., and Kisara K. Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test. Eur. J. Pharmacol. 314 (1996) 61-67
48. Tan-No K., Terenius L., Silberring J., and Nylander I. Levels of dynorphin peptides in the central nervous system and pituitary gland of the spontaneously hypertensive rat. Neurochem. Int. 31 (1997) 27-32
49. Tan-No K., Taira A., Inoue M., Ohshima K., Sakurada T., Sakurada C., Nylander I., Demuth H.U., Silberring J., Terenius L., Tadano T., and Kisara K. Intrathecal administration of p-hydroxymercuribenzoate or phosphoramidon/bestatin-combined induces antinociceptive effects through different opioid mechanisms. Neuropeptides 32 (1998) 411-415
50. Tan-No K., Taira A., Wako K., Niijima F., Nakagawasai O., Tadano T., Sakurada C., Sakurada T., and Kisara K. Intrathecally administered spermine produces the scratching, biting and licking behavior in mice. Pain 86 (2000) 55-61
51. Tan-No K., Ohshima K., Taira A., Inoue M., Niijima F., Nakagawasai O., Tadano T., Nylander I., Silberring J., Terenius L., and Kisara K. Antinociceptive effect produced by intracerebroventricularly administered dynorphin A is potentiated by p-hydroxymercuribenzoate or phosphoramidon in the mouse formalin test. Brain Res. 891 (2001) 274-280
52. Tan-No K., Cebers G., Yakovleva T., Goh B.H., Gileva I., Reznikov K., Aguilar-Santelises M., Hauser K.F., Terenius L., and Bakalkin G. Cytotoxic effects of dynorphins through nonopioid intracellular mechanisms. Exp. Cell Res. 269 (2001) 54-63
53. Tan-No K., Esashi A., Nakagawasai O., Niijima F., Tadano T., Sakurada C., Sakurada T., Bakalkin G., Terenius L., and Kisara K. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-d-aspartate receptor mechanism. Brain Res. 952 (2002) 7-14
54. Tan-No K., Esashi A., Nakagawasai O., Niijima F., Sakurada C., Sakurada T., Bakalkin G., Terenius L., and Tadano T. Nociceptive behavior induced by poly-l-lysine and other basic compounds involves the spinal NMDA receptors. Brain Res. 1008 (2004) 49-53
55. Tan-No K., Taira A., Nakagawasai O., Niijima F., Demuth H.U., Silberring J., Terenius L., and Tadano T. Differential effects of N-peptidyl-O-acyl hydroxylamines on dynorphin-induced antinociception in the mouse capsaicin test. Neuropeptides 39 (2005) 569-573
56. Tan-No K., Takahashi H., Nakagawasai O., Niijima F., Sato T., Satoh S., Sakurada S., Marinova Z., Yakovleva T., Bakalkin G., Terenius L., and Tadano T. Pronociceptive role of dynorphins in uninjured animals: N-Ethylmaleimide-induced nociceptive behavior mediated through inhibition of dynorphin degradation. Pain 113 (2005) 301-309
57. Tan-No K., Esashi A., Nakagawasai O., Niijima F., Furuta S., Sato T., Satoh S., Yasuhara H., and Tadano T. Intrathecally administered D-cycloserine produces nociceptive behavior through the activation of N-methyl-d-aspartate receptor ion-channel complex acting on the glycine recognition site. J. Pharmacol. Sci. 104 (2007) 39-45
58. Tan-No K., Shimoda M., Sugawara M., Nakagawasai O., Niijima F., Watanabe H., Furuta S., Sato T., Satoh S., Arai Y., Kotlinska J., Silberring J., et al. Cysteine protease inhibitors suppress the development of tolerance to morphine antinociception. Neuropeptides 42 (2008) 239-244
59. Tsuji M., Yamazaki M., Takeda H., Matsumiya T., Nagase H., Tseng L.F., Narita M., and Suzuki T. The novel κ-opioid receptor agonist, TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur. J. Pharmacol. 394 (2000) 91-95
60. Vanderah T.W., Laughlin T., Lashbrook J.M., Nichols M.L., Wilcox G.L., Ossipov M.H., Malan T.P., and Porreca F. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: Blockade by MK-801 but not naloxone. Pain 68 (1996) 275-281
61. Vlaskovska M., Nylander I., Schramm M., Hahne S., Kasakov L., Silberring J., and Terenius L. Opiate modulation of dynorphin conversion in primary cultures of rat cerebral cortex. Brain Res. 760 (1997) 85-93
62. Wagner R., and Deleo J.A. Pre-emptive dynorphin and N-methyl-d-aspartate glutamate receptor antagonism alters spinal immunocytochemistry but not allodynia following complete peripheral nerve injury. Neuroscience 72 (1996) 527-534
63. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., Hruby V.J., Malan T.P., Lai J., and Porreca F. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J. Neurosci. 21 (2001) 1779-1786
64. Werz M.A., and Macdonald R.L. Dynorphin and neoendorphin peptides decrease dorsal root ganglion neuron calcium-dependent action potential duration. J. Pharmacol. Exp. Ther. 234 (1985) 49-56
65. Wiley J.W., Moises H.C., Gross R.A., and MacDonald R.L. Dynorphin A-mediated reduction in multiple calcium currents involves a G (o) alpha-subtype G protein in rat primary afferent neurons. J. Neurophysiol. 77 (1997) 1338-1348
66. 3H] MK-801 to the N-methyl-d-aspartate receptor: Pharmacological evidence for the existence of a polyamine recognition site. Mol. Pharmacol. 36 (1989) 575-581
67. Williams K., Romano C., Dichter M.A., and Molinoff P.B. Modulation of the NMDA receptor by polyamines. Life Sci. 48 (1991) 469-498
68. Xie G.X., and Goldstein A. Characterization of big dynorphins from rat brain and spinal cord. J. Neurosci. 7 (1987) 2049-2055
69. Xu M., Petraschka M., McLaughlin J.P., Westenbroek R.E., Caron M.G., Lefkowitz R.J., Czyzyk T.A., Pintar J.E., Terman G.W., and Chavkin C. Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J. Neurosci. 24 (2004) 4576-4584
70. Yamamoto T., Ohno M., and Ueki S. A selective κ-opioid agonist, U-50,488, blocks the development of tolerance to morphine analgesia in rat. Eur. J. Pharmacol. 156 (1988) 173-176
71. Zachariou V., and Goldstein B.D. Dynorphin-(1-8) inhibits the release of substance P-like immunoreactivity in the spinal cord of rats following a noxious mechanical stimulus. Eur. J. Pharmacol. 323 (1997) 159-165
72. Zhang Y.Q., Ji G.C., Wu G.C., and Zhao Z.Q. Excitatory amino acid receptor antagonists and electroacupuncture synergetically inhibit carrageenan-induced behavioral hyperalgesia and spinal fos expression in rats. Pain 99 (2002) 525-535